Clinical Research Directory

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

Sponsor: ADARx Pharmaceuticals, Inc.

Summary

Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.

Official title: A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Key Details

Conditions

Interventions